Biotechnology company Advanced Enzyme Technologies announced Q1FY26 results Revenue from operations on consolidated basis increased to Rs 1,859 million in the Q1FY26 from Rs 1,545 million in the Q1FY25, a growth of 20%. Consolidated EBITDA during Q1FY26 stands at Rs 564 million as compared to Rs 512 million during Q1FY25, an increase of 10%. EBITDA margin stands at 30%, PBT margin stands at 30% and PAT margin stands at 22% during the quarter. Profit before tax stands at Rs 549 million during Q1FY26 as against Rs 487 million in Q1FY25, an increase of 13%. Profit after tax grew by 16% and stands at Rs 404 million during Q1FY26 as compared to Rs 350 million during the Q1FY25. Financial costs stood at Rs 8 million during Q1FY26 as against Rs 9 million in Q1FY25. Depreciation and Amortization charge for the Q1FY26 stood at Rs 96 million as compared to Rs 86 million in Q1FY25. Earnings Per Share during Q1FY26 stands at Rs 3.57 as compared to Rs 3.05 in Q1FY25. Result PDF
Biotechnology company Advanced Enzyme Technologies announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from operations on consolidated basis increased to Rs 1,672 million in the Q4FY25 from Rs 1,578 million in the Q4FY24, a growth of 6% EBITDA margin stands at 27%, PBT margin stands at 26% and PAT margin stands at 16% during the quarter Consolidated EBITDA during Q4FY25 stands at Rs 456 million as compared to Rs 554 million during Q4FY24, declined by 18% Profit before tax stands at Rs 435 million during Q4FY25 as against Rs 396 million in Q4FY24, increase of 9% Profit after tax de-grew by 11% and stands at Rs 267 million during Q4FY25 as compared to Rs 299 million during the Q4FY24 Earnings Per Share during Q4FY25 stands at Rs 2.37 as compared to Rs 2.53 in Q4FY24 FY25 Financial Highlights: Revenue from operations on consolidated basis increased to Rs 6,369 million in the FY25 from Rs 6,239 million in the FY24, reported increase of 2% EBITDA margin stands at 31%, PBT margin stands at 29% and PAT margin stands at 21% during the FY25 Consolidated EBITDA during FY25 stands at Rs 1,944 million as compared to Rs 2,045 million during FY24, declined by 5% Profit before tax stands at Rs 1,874 million during FY25 as against Rs 1,879 million in FY24 Profit after tax stands at Rs 1,340 million during FY25 as compared to Rs 1,370 million during the FY24, declined by 2% Earnings Per Share during FY25 stands at Rs 11.72 as compared to Rs 11.92 in FY24 Result PDF
Biotechnology company Advanced Enzyme Technologies announced Q3FY25 results Revenue from operations on consolidated basis increased to Rs 1,691 million in the Q3FY25 from Rs 1,461 million in the Q2FY25, a growth of 16%. Consolidated EBITDA during Q3FY25 stands at Rs 553 million as compared to Rs 424 million during Q2FY25, increase of 30%. Profit before tax stands at Rs 530 million during Q3FY25 as against Rs 422 million in Q2FY25, increase of 26%. Profit after tax grew by 16% and stands at Rs 389 million during Q3FY25 as compared to Rs 334 million during the Q2FY25. Financial costs remained unchanged during Q3FY25 as compared to Q2FY25. Depreciation and Amortization charge for the Q3FY25 is Rs 90 million as compared to Rs 89 million in Q2FY25. Earnings Per Share during Q3FY25 stands at Rs 3.37 as compared to Rs 2.94 in Q2FY25. Result PDF
Biotechnology company Advanced Enzyme Technologies announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Revenue from operations on consolidated basis decreased to Rs 1,461 million in the Q2FY25 from Rs 1,578 million in the Q2FY24, a de-growth of 7%. Consolidated EBITDA during Q2FY25 stands at Rs 424 million as compared to Rs 513 million during Q2FY24, decrease of 17%. Profit before tax stands at Rs 422 million during Q2FY25 as against Rs 479 million in Q2FY24, decrease of 12%. Profit after tax de-grew by 5% and stands at Rs 334 million during Q2FY25 as compared to Rs 352 million during the Q2FY24. EBITDA margin stands at 29%, PBT margin stands at 29% and PAT margin stands at 23% during the quarter. Financial costs stood at Rs 9 million during Q2FY25 as against Rs 7 million in Q2FY24. Depreciation and Amortization charge for the Q2FY25 stood at Rs 89 million as compared to Rs 87 million Q2FY24. Earnings Per Share during Q2FY25 stands at Rs 2.94 as compared to Rs 3.08 in Q2FY24. H1FY25 Financial Highlights: Revenue from operations on consolidated basis decreased to Rs 3,006 million in the H1FY25 from Rs 3,051 million in the H1FY24, reported decrease of 1%. Consolidated EBITDA during H1FY25 stands at Rs 936 million as compared to Rs 953 million during H1FY24, de-growth of 2%. Profit before tax stands at Rs 909 million during H1FY25 as against Rs 893 million in H1FY24, an increase of 2%. Profit after tax stands at Rs 684 million during H1FY25 as compared to Rs 646 million during the H1FY24, an increase of 6%.. EBITDA margin stands at 31%, PBT margin stands at 30% and PAT margin stands at 23% during the H1FY25. Financial costs stood at Rs 18 million during H1FY25 as against Rs 14 million in H1FY24. Depreciation and Amortization charge for the H1FY25 is Rs 175 million as compared to Rs 174 million in H1FY24. Earnings Per Share during H1FY25 stands at Rs 5.99 as compared to Rs 5.65 in H1FY24. Result PDF
Biotechnology company Advanced Enzyme Technologies announced Q1FY25 results: Revenue from Operations: Revenue from operations on consolidated basis increased to Rs 1,545 million in the Q1FY25 from Rs 1,473 million in the Q1FY24, a growth of 5%. Profit: Consolidated EBITDA during Q1FY25 stands at Rs 512 million as compared to Rs 440 million during Q1FY24, an increase of 16%. Profit before tax stands at Rs 487 million during Q1FY25 as against Rs 414 million in Q1FY24, an increase of 18%. Profit after tax grew by 19% and stands at Rs 350 million during Q1FY25 as compared to Rs 294 million during the Q1FY24. Margin: EBITDA margin stands at 33%, PBT margin stands at 31% and PAT margin stands at 23% during the quarter. Financial Costs: Financial costs stood at Rs 9 million during Q1FY25 as against Rs 7 million in Q1FY24. Depreciation and Amortization: Depreciation and Amortization charge for the Q1FY25 remain unchanged at Rs 86 million as compared to the same quarter previous year. Earnings Per Share: Earnings Per Share during Q1FY25 stands at Rs 3.05 as compared to Rs 2.58 in Q1FY24. Result PDF
Biotechnology company Advanced Enzyme Technologies announced consolidated Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Revenue from Operations: Revenue from operations on consolidated basis increased to Rs 1,578 million in the Q4FY24 from Rs 1,387 million in the Q4FY23, a growth of 14%. Profit: Consolidated EBITDA during Q4FY24 stands at Rs 554 million as compared to Rs 441 million during Q4FY23, an increase of 26%. Profit before tax stands at Rs 397 million during Q4FY24 as against Rs 421 million in Q4FY23, decrease of 6%. Profit after tax de-grew by 7% and stands at Rs 299 million during Q4FY24 as compared to Rs 321 million during the Q4FY23. Margin: EBITDA margin stands at 35%, PBT margin stands at 25% and PAT margin stood at 19% during the quarter. Financial Costs: Financial costs stood at Rs 8 million during Q4FY24 as against Rs 6 million in Q4FY23. Depreciation and Amortization: Depreciation and Amortization charge for the Q4FY24 stood at Rs 93 million as compared to Rs 84 million, the same quarter previous year. Earnings Per Share: Earnings Per Share during Q4FY24 stands at Rs 2.53 as compared to Rs 2.87 in Q4FY23. FY24 Financial Highlights: Revenue from Operations: Revenue from operations on consolidated basis increased to Rs 6,239 million in the FY24 from Rs 5,406 million in the FY23, reported an increase of 15%. Profit: Consolidated EBITDA during FY24 stands at Rs 2,045 million as compared to Rs 1,546 million during FY23, growth of 31%. Profit before tax stands at Rs 1,879 million during FY24 as against Rs 1,404 million in FY23, an increase of 34% Profit after tax stands at Rs 1,370 million during FY24 as compared to Rs 1,039 million during the FY23, an increase of 32%. Margin: EBITDA margin stands at 33%, PBT margin stands at 30% and PAT margin stands at 22% during the FY24. Financial Costs: Financial costs stood at Rs 29 million during FY24 as against Rs 24 million in FY23. Depreciation and Amortization: Depreciation and Amortization charge for the FY24 is Rs 353 million as compared to Rs 350 million in FY23. Earnings Per Share: Earnings Per Share during FY24 stands at Rs 11.92 as compared to Rs 9.45 in FY23. Result PDF